PL1711528T3 - Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13 - Google Patents
Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13Info
- Publication number
- PL1711528T3 PL1711528T3 PL04815598T PL04815598T PL1711528T3 PL 1711528 T3 PL1711528 T3 PL 1711528T3 PL 04815598 T PL04815598 T PL 04815598T PL 04815598 T PL04815598 T PL 04815598T PL 1711528 T3 PL1711528 T3 PL 1711528T3
- Authority
- PL
- Poland
- Prior art keywords
- allergic
- treatment
- asthma
- antibodies
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53213003P | 2003-12-23 | 2003-12-23 | |
PCT/US2004/043541 WO2005062972A2 (en) | 2003-12-23 | 2004-12-23 | Treatment of cancer with novel anti-il 13 monoclonal antibodies |
EP04815598A EP1711528B1 (en) | 2003-12-23 | 2004-12-23 | Treatment of cancer with novel anti-il 13 monoclonal antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1711528T3 true PL1711528T3 (pl) | 2012-11-30 |
Family
ID=34738751
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL20155148.8T PL3718564T3 (pl) | 2003-12-23 | 2004-12-23 | Nowe przeciwciała anty-IL 13 i ich zastosowania |
PL04815598T PL1711528T3 (pl) | 2003-12-23 | 2004-12-23 | Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13 |
PL04815562T PL1703893T3 (pl) | 2003-12-23 | 2004-12-23 | Nowe przeciwciała anty-IL 13 i ich zastosowania |
PL14164624T PL2805728T3 (pl) | 2003-12-23 | 2004-12-23 | Nowe przeciwciała anty-IL13 i ich zastosowania |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL20155148.8T PL3718564T3 (pl) | 2003-12-23 | 2004-12-23 | Nowe przeciwciała anty-IL 13 i ich zastosowania |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04815562T PL1703893T3 (pl) | 2003-12-23 | 2004-12-23 | Nowe przeciwciała anty-IL 13 i ich zastosowania |
PL14164624T PL2805728T3 (pl) | 2003-12-23 | 2004-12-23 | Nowe przeciwciała anty-IL13 i ich zastosowania |
Country Status (24)
Country | Link |
---|---|
US (10) | US7674459B2 (pl) |
EP (6) | EP1711528B1 (pl) |
JP (5) | JP4943161B2 (pl) |
KR (5) | KR101627588B1 (pl) |
CN (4) | CN1973053B (pl) |
AT (1) | ATE552850T1 (pl) |
AU (1) | AU2004308494B2 (pl) |
CA (2) | CA2550651C (pl) |
CY (2) | CY1113009T1 (pl) |
DK (4) | DK1703893T3 (pl) |
ES (5) | ES2533084T3 (pl) |
FI (1) | FI3718564T3 (pl) |
HK (3) | HK1108007A1 (pl) |
HR (3) | HRP20231569T1 (pl) |
HU (2) | HUE064610T2 (pl) |
IL (2) | IL176042A (pl) |
LT (2) | LT2805728T (pl) |
MX (1) | MX361174B (pl) |
PL (4) | PL3718564T3 (pl) |
PT (3) | PT2805728T (pl) |
RU (3) | RU2487887C2 (pl) |
SG (4) | SG10201900535UA (pl) |
SI (4) | SI2805728T1 (pl) |
WO (2) | WO2005062967A2 (pl) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
KR101627588B1 (ko) * | 2003-12-23 | 2016-06-07 | 제넨테크, 인크. | 신규 항-il13 항체 및 그 용도 |
CA2555841A1 (en) * | 2004-02-12 | 2005-09-01 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
US20060122377A1 (en) | 2004-02-19 | 2006-06-08 | Genentech, Inc. | CDR-repaired antibodies |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
EP1824886B1 (en) | 2004-11-17 | 2010-12-22 | Amgen Inc. | Fully human monoclonal antibodies to il-13 |
SI1942939T2 (sl) * | 2005-09-30 | 2021-11-30 | Medimmune Limited | Sestavek protitelesa proti interlevkinu-13 |
US20070202106A1 (en) * | 2005-10-06 | 2007-08-30 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
CA2658833A1 (en) * | 2005-10-06 | 2007-04-19 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
EP1957530A2 (en) | 2005-10-21 | 2008-08-20 | Novartis AG | Human antibodies against il13 and therapeutic uses |
KR101667623B1 (ko) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
JP2009523460A (ja) * | 2006-01-24 | 2009-06-25 | ドマンティス リミテッド | Il−4および/またはil−13に結合するリガンド |
EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
NZ599144A (en) | 2006-09-08 | 2013-10-25 | Abbott Lab | Interleukin -13 binding proteins |
RU2475265C2 (ru) | 2007-01-16 | 2013-02-20 | Эбботт Лэборетриз | Способы лечения псориаза |
CN101977935A (zh) * | 2007-04-23 | 2011-02-16 | 惠氏公司 | 用于治疗和监测il-13相关病症的方法和组合物 |
WO2008140455A1 (en) * | 2007-05-15 | 2008-11-20 | Tanox, Inc. | Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies |
US8183982B2 (en) | 2007-08-14 | 2012-05-22 | Infineon Technologies Ag | System including reply signal that at least partially overlaps request |
CN103223165B (zh) * | 2007-08-24 | 2015-02-11 | 学校法人庆应义塾 | 肿瘤细胞所导致的免疫抑制的解除剂及使用该解除剂的抗肿瘤剂 |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
TWI461210B (zh) | 2008-03-18 | 2014-11-21 | Abbvie Inc | 治療牛皮癬的方法 |
NZ601815A (en) * | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
MX2011001909A (es) | 2008-08-20 | 2011-03-21 | Centocor Ortho Biotech Inc | Anticuerpos anti-interleucina-13 modificados, composiciones, metodos y usos. |
PE20150222A1 (es) | 2008-09-03 | 2015-03-02 | Genentech Inc | Anticuerpos multiespecificos |
US20110236380A1 (en) * | 2008-11-26 | 2011-09-29 | De Wildt Rudolf M T | Ligands that bind il-13 |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
CA2796633C (en) | 2010-04-23 | 2020-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
EP3447491A3 (en) | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
ES2634098T3 (es) | 2011-01-14 | 2017-09-26 | The Regents Of The University Of California | Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos. |
BR112013019499B1 (pt) | 2011-02-04 | 2023-01-10 | Genentech, Inc. | Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
WO2012125775A1 (en) | 2011-03-16 | 2012-09-20 | Sanofi | Uses of a dual v region antibody-like protein |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
AU2012318752B2 (en) | 2011-10-03 | 2017-08-31 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
KR20140084078A (ko) * | 2011-10-31 | 2014-07-04 | 제넨테크, 인크. | 항체 제제 |
KR101483335B1 (ko) | 2011-11-01 | 2015-01-15 | 울산대학교 산학협력단 | 골 손실 진단 마커로서의 피브리노겐의 용도 |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
BR112014023348A2 (pt) * | 2012-03-27 | 2019-03-19 | Genentech, Inc. | Métodos de prognóstico, de diagnóstico e tratamento |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
CN104507537A (zh) * | 2012-07-13 | 2015-04-08 | 宾夕法尼亚大学董事会 | 用于调节car t细胞的组合物和方法 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
KR20150139905A (ko) * | 2013-04-05 | 2015-12-14 | 제넨테크, 인크. | 항-il-4 항체 및 이중특이적 항체 및 그의 용도 |
EP4331605A3 (en) * | 2013-09-13 | 2024-05-22 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
CN105722992B (zh) | 2013-09-13 | 2021-04-20 | 豪夫迈·罗氏有限公司 | 用于检测和定量细胞系和重组多肽产物中的宿主细胞蛋白的组合物和方法 |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
KR20160124165A (ko) * | 2014-02-21 | 2016-10-26 | 제넨테크, 인크. | 항-il-13/il-17 이중특이적 항체 및 그의 용도 |
CN106536754B (zh) * | 2014-04-11 | 2021-04-16 | 诺华股份有限公司 | 用il-13拮抗剂选择性治疗哮喘的方法 |
KR20220119179A (ko) * | 2014-06-18 | 2022-08-26 | 메디뮨 엘엘씨 | N-아세틸시스테인을 포함하는 세포 배양 방법 및 배지 |
JP6770966B2 (ja) | 2014-11-05 | 2020-10-21 | ジェネンテック, インコーポレイテッド | 細菌における2鎖タンパク質の生成方法 |
US10112994B2 (en) * | 2014-11-05 | 2018-10-30 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
MX2017006094A (es) | 2014-11-10 | 2017-07-19 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos. |
EP3271723A1 (en) * | 2015-03-16 | 2018-01-24 | F. Hoffmann-La Roche AG | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
AU2016252773B2 (en) | 2015-04-24 | 2022-06-02 | Genentech, Inc. | Multispecific antigen-binding proteins |
EP3913052A1 (en) | 2015-04-24 | 2021-11-24 | F. Hoffmann-La Roche AG | Methods of identifying bacteria comprising binding polypeptides |
LT3528838T (lt) | 2016-09-23 | 2023-10-10 | F. Hoffmann-La Roche Ag | Il-13 antagonistų panaudojimas gydant atopinį dermatitą |
CA3044526A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
UA126574C2 (uk) | 2017-02-10 | 2022-11-02 | Дженентек, Інк. | Антитіло проти триптази, його композиція та застосування |
WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
AU2018254542B2 (en) | 2017-04-21 | 2022-12-22 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
CN109776677B (zh) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理(江苏)有限公司 | 一种人源化抗il-13抗体及其制备方法和应用 |
CN113101364B (zh) | 2018-05-29 | 2023-12-01 | 康诺亚生物医药科技(成都)有限公司 | 一种自免疫抑制剂的开发和应用 |
WO2020006486A1 (en) * | 2018-06-29 | 2020-01-02 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
WO2020014650A1 (en) * | 2018-07-13 | 2020-01-16 | Memorial Sloan Kettering Cancer Center | Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer |
EP3883636A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2020180727A1 (en) | 2019-03-06 | 2020-09-10 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
CN113795514A (zh) * | 2019-05-09 | 2021-12-14 | 豪夫迈·罗氏有限公司 | 制备抗体的方法 |
US20200352958A1 (en) * | 2019-05-10 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Methods And Compositions For Targeting Retinoic Acid For Solid Tumor Immunotherapy |
AU2020368369A1 (en) | 2019-10-15 | 2022-05-12 | Eli Lilly And Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
TW202144410A (zh) | 2020-03-13 | 2021-12-01 | 美商建南德克公司 | 抗介白素-33抗體及其用途 |
TW202317191A (zh) | 2021-07-16 | 2023-05-01 | 美商德米拉股份有限公司 | 用於治療異位性皮炎之il-13抗體 |
TW202323291A (zh) | 2021-08-13 | 2023-06-16 | 美商德米拉股份有限公司 | 用於治療異位性皮膚炎之il-13抗體 |
CA3230946A1 (en) | 2021-09-15 | 2023-03-23 | Renata Gontijo LIMA | Il-13 inhibitors for the treatment of prurigo nodularis |
WO2023130010A1 (en) | 2021-12-30 | 2023-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
WO2023209568A1 (en) * | 2022-04-26 | 2023-11-02 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
CN118005784A (zh) * | 2022-11-08 | 2024-05-10 | 上海洛启生物医药技术有限公司 | 抗il-13长效纳米抗体序列及其应用 |
Family Cites Families (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
DE3127674A1 (de) | 1981-07-14 | 1983-02-24 | Rheinmetall GmbH, 4000 Düsseldorf | Verfahren und vorrichtung zum belegen einer zielflaeche mit munition |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
DE68921982T4 (de) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5011778A (en) | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
MX9203401A (es) | 1989-12-20 | 1992-07-01 | Schering Corp | Anticuerpos antagonistas de la interleukina-4 humana. |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
JP3583420B2 (ja) | 1990-10-05 | 2004-11-04 | メダレツクス・インコーポレーテツド | 二特異的試薬を用いた標的免疫化 |
ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
DK0574395T3 (da) | 1990-11-09 | 2002-10-07 | Stephen D Gillies | Cytokin-immunkonjugater |
DK0506574T3 (da) | 1991-03-29 | 1996-04-09 | Sanofi Sa | Protein med aktivitet af cytokintype, rekombinant-DNA, der koder for dette protein, celler og transformerede mikroorganismer |
EP0511011B1 (en) | 1991-04-26 | 1996-10-23 | Surface Active Limited | Novel antibodies and methods for their use |
ES2154637T3 (es) | 1991-05-14 | 2001-04-16 | Univ Connecticut | Aportacion de genes dirigidos que codifican proteinas inmunogenicas. |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
CA2103371C (en) | 1991-06-05 | 2003-09-16 | George Y. Wu | Targeted delivery of genes encoding secretory proteins |
US6329509B1 (en) | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
US5965709A (en) | 1991-08-14 | 1999-10-12 | Genentech, Inc. | IgE antagonists |
US5994514A (en) | 1991-08-14 | 1999-11-30 | Genentech, Inc. | Immunoglobulin variants |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
WO1993020221A1 (en) | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5318564A (en) | 1992-05-01 | 1994-06-07 | Hemostatic Surgery Corporation | Bipolar surgical snare and methods of use |
WO1993025788A1 (en) | 1992-06-09 | 1993-12-23 | Hoppe Ag | Latch and lockset system |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5596072A (en) | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
CN1085953A (zh) * | 1992-08-21 | 1994-04-27 | 先灵公司 | 人白细胞介素13 |
EP0656947A1 (en) | 1992-08-21 | 1995-06-14 | Schering Corporation | Human interleukin-13 |
JPH08501085A (ja) | 1992-08-26 | 1996-02-06 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗腫瘍剤としてのサイトカインip−10の利用 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
AU689758B2 (en) | 1992-10-09 | 1998-04-09 | Advanced Tissue Sciences, Inc. | Liver reserve cells |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
PT721469E (pt) | 1993-09-02 | 2000-04-28 | Dartmouth College | Anticorpos anti-gp39 e suas utilizacoes2 |
RU2162711C2 (ru) * | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
IT1270662B (it) * | 1994-10-13 | 1997-05-07 | Applied Research Systems | Antagonista della interleuchina-1 |
US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US6518061B1 (en) | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
ES2317646T3 (es) | 1995-09-08 | 2009-04-16 | Genzyme Corporation | Vectores aav mejorados para terapia genica. |
US6911530B1 (en) | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
WO1997015663A1 (en) | 1995-10-23 | 1997-05-01 | Amrad Operations Pty. Ltd. | A novel haemopoietin receptor and genetic sequences encoding same |
FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
US7078494B1 (en) | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
CA2248868A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
AU6450196A (en) | 1996-06-12 | 1998-01-07 | Human Genome Sciences, Inc. | Hr-1 receptor |
WO1998010638A1 (en) | 1996-09-10 | 1998-03-19 | Amrad Operations Pty. Ltd. | Therapeutic molecules |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
GB9625899D0 (en) | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
US6743604B1 (en) | 1996-12-13 | 2004-06-01 | Smithkline Beecham Corporation | Substances and their uses |
EE9900273A (et) | 1997-01-10 | 2000-02-15 | Biogen, Incorporated | Luupusnefriidi ravi CD40L-vastaste ühenditega |
US6132730A (en) | 1997-01-22 | 2000-10-17 | Board Of Regents, The University Of Texas System | Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment |
RU2224766C2 (ru) | 1997-04-14 | 2004-02-27 | Микромет Аг | Способ получения рецепторов для человеческих антигенов и их применение |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
CA2309541C (en) | 1997-11-03 | 2011-01-11 | Human Genome Sciences, Inc. | Vegi, an inhibitor of angiogenesis and tumor growth |
US6576232B1 (en) | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
US6482403B1 (en) | 1998-05-29 | 2002-11-19 | Heska Corporation | Caniney IL-13 immunoregulatory proteins and uses thereof |
US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
US6222971B1 (en) | 1998-07-17 | 2001-04-24 | David Slobodin | Small inlet optical panel and a method of making a small inlet optical panel |
GB9820014D0 (en) | 1998-09-14 | 1998-11-04 | Cancer Res Campaign Tech | Receptor antagonists and uses thereof |
DE19848026A1 (de) | 1998-10-17 | 2000-04-20 | Bayer Ag | Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen |
CN104611339A (zh) | 1998-12-14 | 2015-05-13 | 遗传研究所有限责任公司 | 细胞因子受体链 |
US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
US6567436B1 (en) | 1999-01-26 | 2003-05-20 | California Institute Of Technology | Opto-electronic oscillators having optical resonators |
US6468528B1 (en) | 1999-02-01 | 2002-10-22 | Amgen Canada Inc. | Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth |
EP1222212A4 (en) * | 1999-10-06 | 2005-05-04 | Penn State Res Found | MUTANTS OF IL-13 |
CA2404763A1 (en) | 1999-11-11 | 2001-05-17 | Raj K. Puri | Mutated il-13 molecules and their uses |
US7422376B2 (en) | 1999-12-07 | 2008-09-09 | Molex Incorporated | Self-contained fiber optic connector module |
DE60134962D1 (de) | 2000-03-03 | 2008-09-04 | Kyowa Hakko Kogyo Kk | Anti-ccr4 antikörper und fragmente davon |
CN1323812A (zh) | 2000-05-16 | 2001-11-28 | 上海博德基因开发有限公司 | 一种新的多肽——人白细胞介素-13(il-13)受体11和编码这种多肽的多核苷酸 |
DE60135481D1 (de) | 2000-10-20 | 2008-10-02 | Genetics Inst | Verwendung von il-13 inhibitoren zur behandlung von tumoren |
AU1091802A (en) | 2000-10-20 | 2002-04-29 | Chugai Pharmaceutical Co Ltd | Degraded agonist antibody |
WO2003018635A1 (en) | 2001-08-31 | 2003-03-06 | Kyowa Hakko Kogyo Co., Ltd. | Human cdr-grafted antibodies and antibody fragments thereof |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
WO2003035847A2 (en) | 2001-10-26 | 2003-05-01 | Centocor, Inc. | Il-13 mutein proteins, antibodies, compositions, methods and uses |
CN1321695C (zh) | 2001-11-07 | 2007-06-20 | 赛托斯生物技术公司 | 用于治疗变应性嗜酸细胞性疾病的展示il-5、il-3或嗜酸细胞活化趋化因子的抗原阵列 |
WO2003047632A1 (en) * | 2001-12-04 | 2003-06-12 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
AU2003225727A1 (en) * | 2002-03-08 | 2003-09-22 | Rigel Pharmaceuticals, Inc. | COMPOUNDS THAT MODULATE PROCESSES ASSOCIATED WITH IgE PRODUCTION AND METHODS AND KITS FOR IDENTIFYING AND USING THE SAME |
US20030170724A1 (en) * | 2002-03-08 | 2003-09-11 | Anderson David C. | Methods of identifying target polypeptides |
WO2003086451A1 (en) * | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
ES2384439T3 (es) | 2002-06-14 | 2012-07-04 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Procedimientos de tratamiento y prevención de colitis que se implican IL-13 y células NK-T |
US7374894B2 (en) * | 2002-07-16 | 2008-05-20 | Rigel Pharmaceuticals, Inc. | Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein |
AU2003260748A1 (en) | 2002-08-30 | 2004-03-19 | Glaxo Group Limited | Il-14 vaccine for the treatment of asthma and atopic disorders |
US20060147417A1 (en) | 2002-08-30 | 2006-07-06 | Claire Ashman | Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use |
CN104178491B (zh) * | 2002-09-06 | 2018-07-03 | 安姆根有限公司 | 治疗性人抗-il-1r1单克隆抗体 |
CN102993306B (zh) | 2003-02-01 | 2015-01-28 | 唐纳士公司 | 高亲和力抗人类IgE抗体 |
ATE316077T1 (de) * | 2003-04-25 | 2006-02-15 | Actimis Pharmaceuticals Inc | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten |
GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
KR101627588B1 (ko) * | 2003-12-23 | 2016-06-07 | 제넨테크, 인크. | 신규 항-il13 항체 및 그 용도 |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
SI1942939T2 (sl) | 2005-09-30 | 2021-11-30 | Medimmune Limited | Sestavek protitelesa proti interlevkinu-13 |
EP1957530A2 (en) | 2005-10-21 | 2008-08-20 | Novartis AG | Human antibodies against il13 and therapeutic uses |
WO2008140455A1 (en) | 2007-05-15 | 2008-11-20 | Tanox, Inc. | Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies |
NZ601815A (en) | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
EP3447491A3 (en) | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
-
2004
- 2004-12-23 KR KR1020147003706A patent/KR101627588B1/ko active IP Right Grant
- 2004-12-23 CN CN2004800386571A patent/CN1973053B/zh active Active
- 2004-12-23 SG SG10201900535UA patent/SG10201900535UA/en unknown
- 2004-12-23 SG SG10201404273QA patent/SG10201404273QA/en unknown
- 2004-12-23 PL PL20155148.8T patent/PL3718564T3/pl unknown
- 2004-12-23 US US10/583,926 patent/US7674459B2/en active Active
- 2004-12-23 HU HUE20155148A patent/HUE064610T2/hu unknown
- 2004-12-23 SI SI200432492T patent/SI2805728T1/sl unknown
- 2004-12-23 PL PL04815598T patent/PL1711528T3/pl unknown
- 2004-12-23 SG SG2012070413A patent/SG184774A1/en unknown
- 2004-12-23 PL PL04815562T patent/PL1703893T3/pl unknown
- 2004-12-23 EP EP04815598A patent/EP1711528B1/en active Active
- 2004-12-23 CN CNA2004800388204A patent/CN1898264A/zh active Pending
- 2004-12-23 WO PCT/US2004/043501 patent/WO2005062967A2/en active Application Filing
- 2004-12-23 DK DK04815562.6T patent/DK1703893T3/da active
- 2004-12-23 HU HUE14164624A patent/HUE049161T2/hu unknown
- 2004-12-23 JP JP2006547441A patent/JP4943161B2/ja active Active
- 2004-12-23 HR HRP20231569TT patent/HRP20231569T1/hr unknown
- 2004-12-23 CN CN201410077001.6A patent/CN104013957B/zh active Active
- 2004-12-23 PT PT141646240T patent/PT2805728T/pt unknown
- 2004-12-23 ES ES10179775.1T patent/ES2533084T3/es active Active
- 2004-12-23 SI SI200432525T patent/SI3718564T1/sl unknown
- 2004-12-23 PT PT201551488T patent/PT3718564T/pt unknown
- 2004-12-23 KR KR1020157014126A patent/KR20150064250A/ko not_active Application Discontinuation
- 2004-12-23 ES ES14164624T patent/ES2775204T3/es active Active
- 2004-12-23 AT AT04815562T patent/ATE552850T1/de active
- 2004-12-23 WO PCT/US2004/043541 patent/WO2005062972A2/en active Application Filing
- 2004-12-23 EP EP10178487A patent/EP2351584A1/en not_active Withdrawn
- 2004-12-23 LT LTEP14164624.0T patent/LT2805728T/lt unknown
- 2004-12-23 ES ES04815598T patent/ES2390344T3/es active Active
- 2004-12-23 ES ES20155148T patent/ES2967485T3/es active Active
- 2004-12-23 EP EP04815562A patent/EP1703893B1/en active Active
- 2004-12-23 KR KR1020127001379A patent/KR20120020203A/ko active Application Filing
- 2004-12-23 US US10/583,927 patent/US8067199B2/en active Active
- 2004-12-23 PL PL14164624T patent/PL2805728T3/pl unknown
- 2004-12-23 DK DK04815598.0T patent/DK1711528T3/da active
- 2004-12-23 MX MX2015002420A patent/MX361174B/es unknown
- 2004-12-23 CA CA2550651A patent/CA2550651C/en active Active
- 2004-12-23 DK DK14164624.0T patent/DK2805728T3/da active
- 2004-12-23 EP EP14164624.0A patent/EP2805728B1/en active Active
- 2004-12-23 KR KR1020137007978A patent/KR20130041373A/ko active Application Filing
- 2004-12-23 LT LTEP20155148.8T patent/LT3718564T/lt unknown
- 2004-12-23 CN CN201210299210.6A patent/CN102993302B/zh active Active
- 2004-12-23 CA CA2551110A patent/CA2551110C/en active Active
- 2004-12-23 FI FIEP20155148.8T patent/FI3718564T3/fi active
- 2004-12-23 PT PT04815562T patent/PT1703893E/pt unknown
- 2004-12-23 RU RU2006122037/10A patent/RU2487887C2/ru active
- 2004-12-23 SI SI200431888T patent/SI1703893T1/sl unknown
- 2004-12-23 SI SI200431935T patent/SI1711528T1/sl unknown
- 2004-12-23 EP EP10179775.1A patent/EP2332575B1/en active Active
- 2004-12-23 DK DK20155148.8T patent/DK3718564T3/da active
- 2004-12-23 KR KR1020067014859A patent/KR101280338B1/ko active IP Right Grant
- 2004-12-23 EP EP20155148.8A patent/EP3718564B1/en active Active
- 2004-12-23 JP JP2006547431A patent/JP4851944B2/ja active Active
- 2004-12-23 AU AU2004308494A patent/AU2004308494B2/en active Active
- 2004-12-23 SG SG200901976-1A patent/SG151296A1/en unknown
- 2004-12-23 ES ES04815562T patent/ES2385038T3/es active Active
-
2006
- 2006-05-31 IL IL176042A patent/IL176042A/en active IP Right Grant
-
2007
- 2007-01-25 JP JP2007015642A patent/JP2007161724A/ja active Pending
- 2007-11-30 HK HK07113106.7A patent/HK1108007A1/xx unknown
-
2008
- 2008-09-29 US US12/240,604 patent/US8088618B2/en active Active
-
2010
- 2010-01-14 US US12/687,637 patent/US8318160B2/en active Active
- 2010-10-15 JP JP2010233095A patent/JP2011042669A/ja active Pending
-
2011
- 2011-05-18 JP JP2011111913A patent/JP2011200242A/ja not_active Withdrawn
- 2011-10-18 US US13/275,658 patent/US8734797B2/en active Active
- 2011-10-18 US US13/275,684 patent/US8734801B2/en active Active
- 2011-11-30 US US13/308,186 patent/US9067994B2/en active Active
-
2012
- 2012-05-03 HR HRP20120376TT patent/HRP20120376T1/hr unknown
- 2012-05-31 CY CY20121100496T patent/CY1113009T1/el unknown
- 2012-06-05 RU RU2012123148/10A patent/RU2012123148A/ru unknown
-
2013
- 2013-08-20 US US13/971,394 patent/US9605065B2/en active Active
-
2014
- 2014-04-23 IL IL232210A patent/IL232210A0/en unknown
-
2015
- 2015-02-27 HK HK15102008.9A patent/HK1201457A1/xx unknown
- 2015-05-23 HK HK15104923.7A patent/HK1204288A1/xx unknown
-
2017
- 2017-09-29 US US15/721,570 patent/US20180251538A1/en not_active Abandoned
-
2019
- 2019-11-13 US US16/682,773 patent/US11434287B2/en active Active
-
2020
- 2020-02-13 RU RU2020106818A patent/RU2752833C1/ru active
- 2020-04-14 HR HRP20200592TT patent/HRP20200592T1/hr unknown
- 2020-04-28 CY CY20201100385T patent/CY1122817T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1201457A1 (en) | Treatment of cancer with novel anti-il 13 monoclonal antibodies il13 | |
WO2008134659A8 (en) | Antagonists to il-17a, il-17f, and il-23p19 and methods of use | |
TW200612985A (en) | Immunoglobulins | |
TW200503721A (en) | Aminoquinoline compounds | |
NZ600584A (en) | Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof | |
SG146696A1 (en) | Humanized antibodies against vascular endothelial growth factor | |
HK1112941A1 (en) | Use of a33 antigens and jam-it a33 | |
WO2005115452A3 (en) | Fcϝriib-specific antibodies and methods of use thereof | |
IL185754A0 (en) | Novel anti-plgf antibody | |
WO2005056600A3 (en) | Monoclonal antibodies that bind or neutralize dengue virus | |
TW200736274A (en) | Immunoglobulins | |
WO2003073982A3 (en) | Anti-interleukin-1 beta analogs | |
WO2004024098A3 (en) | Method for the treatment of nephritis using anti-pdgf-dd antibodies | |
SG148190A1 (en) | Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer |